These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26645225)

  • 21. Harm avoidance and childhood adversities in patients with obsessive-compulsive disorder and their unaffected first-degree relatives.
    Bey K; Lennertz L; Riesel A; Klawohn J; Kaufmann C; Heinzel S; Grützmann R; Kathmann N; Wagner M
    Acta Psychiatr Scand; 2017 Apr; 135(4):328-338. PubMed ID: 28160276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results.
    Külz AK; Meinzer S; Kopasz M; Voderholzer U
    Neuropsychobiology; 2007; 56(2-3):127-31. PubMed ID: 18259085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are candidate neurocognitive endophenotypes of OCD present in paediatric patients? A systematic review.
    Marzuki AA; Pereira de Souza AMFL; Sahakian BJ; Robbins TW
    Neurosci Biobehav Rev; 2020 Jan; 108():617-645. PubMed ID: 31821834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Volitional saccade performance in a large sample of patients with obsessive-compulsive disorder and unaffected first-degree relatives.
    Bey K; Kloft L; Lennertz L; Grützmann R; Heinzel S; Kaufmann C; Klawohn J; Riesel A; Meyhöfer I; Kathmann N; Wagner M
    Psychophysiology; 2017 Sep; 54(9):1284-1294. PubMed ID: 28481032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder.
    Delorme R; Betancur C; Callebert J; Chabane N; Laplanche JL; Mouren-Simeoni MC; Launay JM; Leboyer M
    Neuropsychopharmacology; 2005 Aug; 30(8):1539-47. PubMed ID: 15886722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive deficits of executive functions and decision-making in obsessive-compulsive disorder.
    Dittrich WH; Johansen T
    Scand J Psychol; 2013 Oct; 54(5):393-400. PubMed ID: 23841985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
    Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
    Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reasoning, problem-solving, and visual learning as candidate endophenotypes for first-episode, drug-naïve obsessive-compulsive disorder in the Han Chinese population.
    Yuan X; Tang J; Chen J; Liu Y; Lai X; Hu M
    Neurosci Lett; 2020 Nov; 738():135377. PubMed ID: 32920047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive endophenotypes in OCD: a study of unaffected siblings of probands with familial OCD.
    Viswanath B; Janardhan Reddy YC; Kumar KJ; Kandavel T; Chandrashekar CR
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):610-5. PubMed ID: 19272409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy.
    Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W
    J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presupplementary motor area hyperactivity during response inhibition: a candidate endophenotype of obsessive-compulsive disorder.
    de Wit SJ; de Vries FE; van der Werf YD; Cath DC; Heslenfeld DJ; Veltman EM; van Balkom AJ; Veltman DJ; van den Heuvel OA
    Am J Psychiatry; 2012 Oct; 169(10):1100-8. PubMed ID: 23032388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escitalopram in the treatment of obsessive-compulsive disorder.
    Zohar J
    Expert Rev Neurother; 2008 Mar; 8(3):339-49. PubMed ID: 18345966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
    Stein DJ; Van Heerden B; Wessels CJ; Van Kradenburg J; Warwick J; Wasserman HJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):1079-99. PubMed ID: 10621951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired volitional saccade control: first evidence for a new candidate endophenotype in obsessive-compulsive disorder.
    Kloft L; Reuter B; Riesel A; Kathmann N
    Eur Arch Psychiatry Clin Neurosci; 2013 Apr; 263(3):215-22. PubMed ID: 22643832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.
    Stein DJ; Carey PD; Lochner C; Seedat S; Fineberg N; Andersen EW
    CNS Spectr; 2008 Jun; 13(6):492-8. PubMed ID: 18567973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.